Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF

Of 4742 pts with a baseline eGFR, 1926 (41%) had eGFR <60 ml/min/1.73m2. The effect of dapagliflozin on cardiovascular death or worsening heart failure did not differ by eGFR category (HR in patients with CKD was 0.71 vs 0.77 with eGFR ≥60 ml/min/1.73m2; p=0.54).

Circulation